| Identification | Back Directory | [Name]
Triproamylin acetate | [CAS]
187887-46-3 | [Synonyms]
Symlin
Triproamylin acetate
Pramlintide acetate salt
Pramlintide acetate(151126-32-8 free base)
Pramlintide acetate(151126 32 8 free base),Pramlintide acetate(151126328 free base) | [Molecular Formula]
C173H271N51O55S2 | [MDL Number]
MFCD08460172 | [MOL File]
187887-46-3.mol | [Molecular Weight]
4009.44 |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [form ]
Solid | [color ]
White to off-white | [Sequence]
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Disulfide bridge:Cys2-Cys7) |
| Hazard Information | Back Directory | [Uses]
Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer[1]. | [Biochem/physiol Actions]
Pramlintide (AC0137, AC137, triPro-amylin) is a synthetic antidiabetic peptide that corresponds to human amylin (aa34-70) with proline substitutions at N25, S28 and S29 to limit the self-aggregation seen with native amylin. Pramlintide augments endogenous amylin-mediated glycemic control (blood glucose regulation) in vivo by delaying gastric emptying and inhibiting the secretion of glucagon, a catabolic hormone that opposes the effects of insulin and amylin. | [References]
[1] Maha S Al-Keilani, et al. Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy. Clin Pharmacol. 2018 Mar 5;10:23-29. DOI:10.2147/CPAA.S153780 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|